mTOR inhibitor

The mTOR kinase exists in two multiprotein complexes, mTORC1 and mTORC2, which differ in their sensitivity to rapamycin and their downstream substrates. mTORC1, which is acutely inhibited by rapamycin, phosphorylates S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1), promoting protein synthesis and cell growth. mTORC2, which is generally rapamycin-insensitive, phosphorylates Akt at Ser473 and regulates cytoskeletal organization. Most first-generation mTOR inhibitors, such as sirolimus (rapamycin), everolimus, and temsirolimus, form a complex with the immunophilin FKBP12 and bind to the FKBP12-rapamycin binding (FRB) domain of mTOR, allosterically inhibiting mTORC1 but not mTORC2. Second-generation ATP-competitive inhibitors, such as AZD8055 and INK128, block both complexes and are in clinical development.

Sirolimus (rapamycin) was approved by the U.S. FDA in 1999 as an immunosuppressant to prevent renal transplant rejection, and its derivative everolimus is used for the same indication as well as for advanced renal cell carcinoma, subependymal giant cell astrocytoma associated with tuberous sclerosis, and hormone receptor-positive breast cancer. Temsirolimus is approved for advanced renal cell carcinoma. These agents are also used in drug-eluting coronary stents to prevent restenosis. In addition, mTOR inhibitors are being studied for their potential to extend lifespan in model organisms, and rapamycin has been shown to extend the lifespan of mice even when treatment is started late in life. Clinical trials are exploring their use in age-related conditions such as Alzheimer's disease and sarcopenia.

Common adverse effects of mTOR inhibitors include stomatitis, hyperlipidemia, hyperglycemia, thrombocytopenia, and interstitial pneumonitis, which can be dose-limiting. Because mTORC1 inhibition relieves the negative feedback loop on insulin receptor substrate-1 (IRS-1), it can paradoxically activate Akt via mTORC2, leading to reduced antitumor efficacy and potential resistance. Resistance to rapalogs can also arise from mutations in the FRB domain of mTOR or from upregulation of upstream receptor tyrosine kinases. Combination strategies with PI3K inhibitors or dual mTORC1/2 inhibitors are being explored to overcome these resistance mechanisms.

Beyond oncology and transplantation, mTOR inhibitors have niche applications: topical sirolimus is used for facial angiofibromas in tuberous sclerosis, and everolimus is used in the treatment of subependymal giant cell astrocytoma. In veterinary medicine, rapamycin has been studied for lifespan extension in dogs. The discovery of rapamycin dates to 1975, when it was isolated from the bacterium Streptomyces hygroscopicus found in a soil sample from Easter Island (Rapa Nui), which is also the source of its name. Interestingly, rapamycin was initially developed as an antifungal agent but was abandoned due to its immunosuppressive properties. Recent research has identified that rapamycin can inhibit the replication of certain viruses, including human cytomegalovirus, and it is being investigated as a potential antiviral therapy.

mTORC1

mTOR complex 1, a rapamycin-sensitive complex that regulates protein synthesis and cell growth.

mTORC2

mTOR complex 2, a rapamycin-insensitive complex that phosphorylates Akt and regulates cell survival.

Rapalog

A rapamycin analog, such as everolimus or temsirolimus, that inhibits mTORC1.

FKBP12

An immunophilin that binds rapamycin and mediates its interaction with mTOR.